Showing 2981-2990 of 9123 results for "".
Scientifically Speaking: Applying Energy-Based Devices Across Skin Tones
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-applying-energy-based-devices-across-skin-tones/19895/With advancements in technology and a patient-focused approach to treatment, it's possible to safely and effectively apply energy-based devices to a range of skin concerns in patients with darker skin. Host Joel L. Cohen, MD discusses treatment strategies for melasma, acne, PFB, scarring and more wiAllergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focL'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireQuantel Derma LEDA Diode Laser System - Hair Removal at the Speed of Light
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/quantel-derma-leda-diode-laser-system-hair-removal-at-the-speed-of-light/19447/LEDA is the expandable platform system for permanent hair removal at the speed of light. LEDA applies photodynamic therapy (PDT) for the treatment of acne, Psoriasis, Vitiligo & atopic dermatitis, and for gentle skin rejuvenation. The diode laser system LEDA EPI, for hair removal, has a large spCurrent and Future Treatments
https://practicaldermatology.com/series/updates-vitiligo/current-and-future-treatments/26622/Dr. Karan Lal, a double board-certified adult and pediatric dermatologist and fellowship-trained cosmetic dermatologist with Affiliated Dermatology in Scottsdale, Arizona, talks with Practical Dermatology about the various options available today for repigmentation and treating flare-ups in vitiligoSCALE 2024: Dr. Hilary Baldwin’s Tips and Tricks for Treating Keloids
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwins-tips-and-tricks-for-treating-keloids/26366/Hilary E. Baldwin, MD, discusses best practices for the treatment of keloids at Music City SCALE.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinClinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study